newsfilter
← Latest News
Business Wire·

LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates

Company expects package will not require additional human clinical studies, potentially accelerating path to market LadRx Corporation (OTCQB:LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on